- Home
- ANTX vs DHF Comparison
ANTX vs DHF Comparison
Compare ANTX & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANTX | DHF |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.9M | 170.2M |
| IPO Year | 2022 | 1998 |
Fundamental Metrics
Financial Performance| Metric | ANTX | DHF |
|---|---|---|
| Price | $5.83 | $2.37 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | 196.2K | ★ 283.8K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $2.32 |
| 52 Week High | $7.19 | $2.63 |
Technical Indicators
Market Signals| Indicator | ANTX | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 58.96 | 44.68 |
| Support Level | $3.91 | $2.32 |
| Resistance Level | $6.91 | $2.42 |
| Average True Range (ATR) | 0.49 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 38.43 | 36.36 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.